Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Atypical Teratoid/Rhabdoid Tumors
NCT06853080Phase 2Active, not recruiting
- Sponsor
- Taipei Medical University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in Atypical teratoid rhabdoid tumor (ATRT), sponsored by Taipei Medical University. Started Dec 2020; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT06853080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853080.